BACKGROUND: Chinese sirolimus-eluting stents (SES) have been widely used in recent years. However, the comparison of clinical outcomes between Chinese and foreign SES remains unknown. OBJECTIVES: To compare the outcomes of Chinese SES (Firebird) with foreign SES (Cypher Select) in the treatment of patients undergoing percutaneous coronary intervention (PCI). METHODS: 4000 consecutive patients treated with SESs from January 2008 to December 2009 were included in this study. Based on the differences of the stents, the patients were divided into a Chinese SES group (Firebird; n = 2008) and a foreign SES group (Cypher Select; n = 1992). Outcomes were monitored for 1 year. The primary clinical endpoint was major adverse cardiac events (MACE): a composite of death, non-fatal myocardial infarction (MI) and target-vessel revascularisation (TVR). RESULTS: No differences were observed in the incidence of MACE (17.8% vs. 18.6%, p = 0.514) and TVR rate (9.0% vs. 8.6%, p = 0.632) during 1-year follow-up. CONCLUSIONS: Chinese SES and foreign SES have similar effects on 1-year clinical outcomes and safety.
BACKGROUND: Chinese sirolimus-eluting stents (SES) have been widely used in recent years. However, the comparison of clinical outcomes between Chinese and foreign SES remains unknown. OBJECTIVES: To compare the outcomes of Chinese SES (Firebird) with foreign SES (Cypher Select) in the treatment of patients undergoing percutaneous coronary intervention (PCI). METHODS: 4000 consecutive patients treated with SESs from January 2008 to December 2009 were included in this study. Based on the differences of the stents, the patients were divided into a Chinese SES group (Firebird; n = 2008) and a foreign SES group (Cypher Select; n = 1992). Outcomes were monitored for 1 year. The primary clinical endpoint was major adverse cardiac events (MACE): a composite of death, non-fatal myocardial infarction (MI) and target-vessel revascularisation (TVR). RESULTS: No differences were observed in the incidence of MACE (17.8% vs. 18.6%, p = 0.514) and TVR rate (9.0% vs. 8.6%, p = 0.632) during 1-year follow-up. CONCLUSIONS: Chinese SES and foreign SES have similar effects on 1-year clinical outcomes and safety.
Authors: C P Cannon; A Battler; R G Brindis; J L Cox; S G Ellis; N R Every; J T Flaherty; R A Harrington; H M Krumholz; M L Simoons; F J Van De Werf; W S Weintraub; K R Mitchell; S L Morrisson; R G Brindis; H V Anderson; D S Cannom; W R Chitwood; J E Cigarroa; R L Collins-Nakai; S G Ellis; R J Gibbons; F L Grover; P A Heidenreich; B K Khandheria; S B Knoebel; H L Krumholz; D J Malenka; D B Mark; C R Mckay; E R Passamani; M J Radford; R N Riner; J B Schwartz; R E Shaw; R J Shemin; D B Van Fossen; E D Verrier; M W Watkins; D R Phoubandith; T Furnelli Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: Jin M Cheng; Yoshinobu Onuma; Nicolo Piazza; Rutger-Jan M Nuis; Ron T Van Domburg; Patrick W Serruys Journal: Am J Cardiol Date: 2010-10-01 Impact factor: 2.778
Authors: Tamir Bental; Abid Assali; Hana Vaknin-Assa; Eli I Lev; David Brosh; Shmuel Fuchs; Alexander Battler; Ran Kornowski Journal: Catheter Cardiovasc Interv Date: 2010-09-01 Impact factor: 2.692
Authors: Albert Schömig; Alban Dibra; Stephan Windecker; Julinda Mehilli; José Suárez de Lezo; Christoph Kaiser; Seung-Jung Park; Jean-Jacque Goy; Jae-Hwan Lee; Emilio Di Lorenzo; Jinjin Wu; Peter Jüni; Matthias E Pfisterer; Bernhard Meier; Adnan Kastrati Journal: J Am Coll Cardiol Date: 2007-08-21 Impact factor: 24.094